BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 29644524)

  • 21. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
    Sagnelli C; Pisaturo M; Calò F; Martini S; Sagnelli E; Coppola N
    World J Gastroenterol; 2019 Jul; 25(26):3299-3312. PubMed ID: 31341357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
    Tan J; Zhou J; Zhao P; Wei J
    Clin Rheumatol; 2012 Aug; 31(8):1169-75. PubMed ID: 22544263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
    Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
    Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
    Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
    Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.
    Mo YQ; Liang AQ; Ma JD; Chen LF; Zheng DH; Schumacher HR; Dai L
    BMC Musculoskelet Disord; 2014 Dec; 15():449. PubMed ID: 25532827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data.
    El Kassas M; Shimakawa Y; Ali-Eldin Z; Funk AL; Wifi MN; Zaky S; El-Raey F; Esmat G; Fontanet A
    Liver Int; 2018 Dec; 38(12):2159-2169. PubMed ID: 29738637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
    Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
    Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
    Wu YT; Li X; Liu ZL; Xu Z; Dai W; Zhang K; Wu JS; Arshad B; Wu KN; Kong LQ
    PLoS One; 2017; 12(6):e0179680. PubMed ID: 28640902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?
    Ekpanyapong S; Reddy KR
    Clin Liver Dis; 2020 Aug; 24(3):317-333. PubMed ID: 32620274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.
    Yoo S; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Yoo C; Ryoo BY; Choi J
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):898-907. PubMed ID: 34182151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
    Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
    Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation.
    Shaikh SA; Kahn J; Aksentijevic A; Kawewat-Ho P; Bixby A; Rendulic T; Park JM
    Transpl Infect Dis; 2022 Feb; 24(1):e13751. PubMed ID: 34725887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
    He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
    Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
    An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.
    Patel A; Yapali S; Lok AS
    Hepatol Int; 2016 Jan; 10(1):139-46. PubMed ID: 26272106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.